A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2001
10/25/2001	US20010033847 Triglyceride
10/25/2001	US20010033832 Methods for treating urinary incontinence in mammals
10/25/2001	US20010033830 Porous particles for deep lung delivery
10/25/2001	US20010033829 Biodegradable material
10/25/2001	US20010033828 Porous particles for deep lung delivery
10/25/2001	US20010032643 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
10/25/2001	DE10020899A1 New 9-oxa-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	DE10020517A1 New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	DE10019275A1 Treating or preventing eye disorders associated with blood-vitreous humor-tissue barrier defects, e.g. cataracts or corneal haze, using fibrinogen receptor antagonists
10/25/2001	DE10019272A1 Medicament for prophylaxis or treatment of cardiac insufficiency, comprising cholesterol synthesis enzyme inhibitor, preferably cerivastatin
10/25/2001	DE10019143A1 Medicament for prophylaxis or treatment of cardiac insufficiency, comprising cholesterol synthesis enzyme inhibitor, preferably cerivastatin
10/25/2001	DE10019062A1 Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
10/25/2001	DE10019052A1 Use of polyunsaturated fatty acids for the treatment of enuresis and incontinence
10/25/2001	DE10018834A1 Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
10/25/2001	DE10018783A1 Stable aqueous ciprofloxacin infusion solutions containing sulfuric acid as the stabilizing agent useful for the treatment of bacterial infections in humans and animals
10/25/2001	DE10018781A1 Aqueous ciprofloxacin infusion solutions containing orthophosphoric acid monoester or diester as solubilizing and stabilizing agent useful for the treatment of bacterial infections
10/25/2001	DE10018401A1 Medicament for treating hypertrophy-related myocardial disease, containing bradycardic agent, preferably cilobradine, and optionally another cardiac drug
10/25/2001	CA2715554A1 Active substance combinations with insecticidal and acaricidal properties
10/25/2001	CA2575059A1 Pharmaceutical compositions comprising cilobradine
10/25/2001	CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001	CA2407065A1 A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
10/25/2001	CA2407063A1 Solid dispersion with improved absorbability
10/25/2001	CA2407031A1 Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
10/25/2001	CA2406947A1 Methods for prevention and treatment of gastrointestinal disorders
10/25/2001	CA2406475A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/25/2001	CA2406442A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001	CA2406403A1 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
10/25/2001	CA2406390A1 Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
10/25/2001	CA2406383A1 A.beta.42 lowering agents
10/25/2001	CA2406226A1 Rapid-onset formulation of a selective cyclooxigenase-2
10/25/2001	CA2406220A1 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001	CA2406192A1 Therapeutic compounds and methods for formulating v3, a versican isoform
10/25/2001	CA2406160A1 Compounds for modulating cell proliferation
10/25/2001	CA2406032A1 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase
10/25/2001	CA2406023A1 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
10/25/2001	CA2405919A1 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives
10/25/2001	CA2405711A1 Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes
10/25/2001	CA2405696A1 5-substituted tetralones as inhibitors of ras farnesyl transferase
10/25/2001	CA2405684A1 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
10/25/2001	CA2405599A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone
10/25/2001	CA2405597A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	CA2405377A1 Nutritional modules
10/25/2001	CA2405238A1 Single-dose antihistamine/decongestant formulations for treating rhinitis
10/25/2001	CA2405233A1 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
10/25/2001	CA2404909A1 Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
10/25/2001	CA2404858A1 Treatment of neurodegenerative disease
10/25/2001	CA2404639A1 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
10/25/2001	CA2404117A1 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
10/25/2001	CA2404097A1 Method and compositions for preventing hormone induced adverse effects
10/25/2001	CA2403591A1 Pharmaceutical compositions comprising fluvastatin
10/25/2001	CA2403547A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
10/25/2001	CA2403508A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001	CA2403490A1 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001	CA2402374A1 Processes for the preparation of thiazolidinedione derivatives and intermediates
10/25/2001	CA2398446A1 Pyrazoles for inhibiting protein kinases
10/25/2001	CA2370487A1 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
10/24/2001	EP1148127A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor). Its uses
10/24/2001	EP1148126A2 Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
10/24/2001	EP1148062A2 Sterol compositions from pulping soap
10/24/2001	EP1148059A1 Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof
10/24/2001	EP1148055A1 C9 taxane derivatives and pharmaceutical compositions containing them
10/24/2001	EP1148054A1 Thyroid receptor ligands
10/24/2001	EP1148053A1 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
10/24/2001	EP1148050A1 Retroviral protease inhibitors
10/24/2001	EP1148049A1 Crystalline R-(R,R)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
10/24/2001	EP1148048A2 Polyaromatic antiviral compositions
10/24/2001	EP1147785A2 Therapeutic light source
10/24/2001	EP1147781A1 Biodegradable implant precursor
10/24/2001	EP1147779A1 A method for rendering ursodeoxycholic acid in soluble form pharmaceutical compositions
10/24/2001	EP1147778A1 Stable gel formulation for topical treatment of skin conditions
10/24/2001	EP1147777A1 Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
10/24/2001	EP1147774A1 Method for improving the quality of sperm for artificial insemination of animals
10/24/2001	EP1147773A1 Medicinal compositions for treating osseous lesion in multiple myeloma
10/24/2001	EP1147771A1 Pharmaceutical formulation containing amoxycillin and clavulanate
10/24/2001	EP1147770A1 Virginiamycin mixture
10/24/2001	EP1147769A2 Use of polyunsaturated fatty acids, especially omega-3-fatty acids, for the treatment of enuresis and incontinence
10/24/2001	EP1147768A1 Transdermal therapeutic system for administering dofetilide
10/24/2001	EP1147767A1 Controlled release formulations of nimesulide and a process for the manufacture thereof
10/24/2001	EP1147766A2 Pharmaceutical compositions
10/24/2001	EP1147422A1 Assays for modulators of "elongation factor p" activity
10/24/2001	EP1147223A1 Identifying, monitoring, and treating women for breast precancer or cancer
10/24/2001	EP1147214A1 A novel method for designing protein kinase inhibitors
10/24/2001	EP1147209A2 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
10/24/2001	EP1147201A2 Metalloproteinase-disintegrin family members: svph dnas and polypeptides
10/24/2001	EP1147193A1 Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
10/24/2001	EP1147191A1 Transcriptional regulation of the human beta3-adrenergic receptor gene
10/24/2001	EP1147188A1 Internal ribosome entry site (ires), vector containing same and the uses thereof
10/24/2001	EP1147175A2 Fibres for culturing eukaryotic cells
10/24/2001	EP1147167A1 Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof
10/24/2001	EP1147138A1 Hydrophilic ampholytic polymer
10/24/2001	EP1147136A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
10/24/2001	EP1147134A1 Novel potassium channels and genes encoding these potassium channels
10/24/2001	EP1147124A2 Steroid sulfatase inhibitors and methods for making and using the same
10/24/2001	EP1147121A2 Ketolide antibiotics
10/24/2001	EP1147119A1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
10/24/2001	EP1147116A1 Boron steroid mimics and pharmaceutical compositions
10/24/2001	EP1147114A1 Novel aralkyl amines of spirofuropyridines useful in therapy
10/24/2001	EP1147113A1 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
10/24/2001	EP1147112A1 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
10/24/2001	EP1147110A1 Pyrazino(aza)indole derivatives

1 ... 5983 5984 5985 5986 5987 5988 5989 5990 5991 5992 5993 5994 5995 5996 5997 5998 5999 6000 6001 6002 6003 ... 7860